Videos

Mario Sznol, MD, professor, Internal Medicine, Yale Cancer Center, discusses a phase I trial that examined the combination of nivolumab and ipilimumab for the treatment of advanced melanoma. The data presented at the 2014 ASCO Annual Meeting was an updated survival and clinical activity analysis in initially enrolled cohorts and activity by BRAF mutation status.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses the goals of the SystHERs Registry.

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the role of heat shock protein 90 (Hsp90) in the treatment of lung cancer.

Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.

David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I study of MEDI3617 for advanced solid tumors.

James L. Mulshine, MD, professor, Associate Provost for Research, Vice President, Rush University Medical Center discusses the correlation between e-cigarettes and smoking cessation.

Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses the next treatment steps for a patient with HER2-negative chemotherapy-resistant metastatic breast cancer.

Linda D. Bosserman, MD, FACP, president, medical oncologist, Wilshire Oncology Medical Group, discusses how she determines if a patient is resistant to a taxane or anthracyclines.

Linda D. Bosserman, MD, FACP, president, medical oncologist, Wilshire Oncology Medical Group, discusses how she would treat a patient with HER2-negative metastatic breast cancer.

Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses how she decides between hormone therapies in patients with ER+/PR+ tumors.

James CH Yang, MD, PhD, Professor of Medicine, Deputy Director, Department of Medical Oncology, National Taiwan University Hospital, Director, Cancer Research, Center National Taiwan University College of Medicine, discusses current practices for administering TKI therapy and the potential for TKI combinations.

Claudine Isaacs, MD, professor, medical Director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses some of the challenges physicians are facing in the field of hereditary breast cancer.

Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses an analysis of chemotherapy administration and survival in soft tissue sarcoma.

David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcoming KRAS mutations in lung cancer.

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).

Edith A. Perez, MD, Breast Cancer: Giant of Cancer Care; deputy director at large, Mayo Clinic Cancer Center, Serene M. and Frances C. Durling professor of Medicine, Division of Hematology/Oncology, discusses a genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.

Joyce A. O’Shaughnessy, MD, from Baylor Charles A. Sammons Cancer Center, discusses the results of a recent breast cancer study.

Michael J. Morris, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the rationale behind TAX 3503 (hormonal therapy +/- docetaxel for patients at high risk of metastatic prostate cancer).

Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses some potential novel treatment modalities for the treatment of sarcoma.

Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, discusses curing and managing late toxicities in testicular cancer.

Andrew Kennedy, MD, physician-in-chief, Radiation Oncology, Sarah Cannon, director, Radiation Oncology Research, Sarah Cannon Research Institute, explains what SIR-Spheres are and how they are used.

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the association of disease progression on ibrutinib therapy with the acquisition of resistance mutations as seen at The Ohio State University Comprehensive Cancer Center.

Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the development of ONT-380, an oral HER2-specific inhibitor, for the treatment of patients with HER2-positive metastatic breast cancer.

Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer.

Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men’s treatment decisions after seeing a rise in their PSA levels. <

Kenneth R. Carson, MD, assistant professor, Division of Oncology, Washington University, discusses post-therapy imaging in lymphoma.

Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses the future of predicting outcomes in breast cancer.

Moben Mirza, MD, assistant professor of urology at the University of Kansas Medical Center, discusses a study that examines the impact of physical activity, obesity, and smoking on bladder cancer mortality.

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the utility of bevacizumab for the treatment of cervical cancer.

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses the utility of Prostate Health Index (PHI).